Baxter receives FDA acceptance for ADVATE to avoid hemophilia A Baxter International Inc.

Emerging data provide important info to greatly help physicians optimize look after hemophilia patients of most ages by preventing unpredicted bleeding events that may have a detrimental effect on the lives of sufferers, stated Leonard Valentino, M.D., Director, Hurry Hemophilia and Thrombophilia Middle and Portion of Pediatric Hematology/Oncology, Rush University INFIRMARY, Chicago, and business lead investigator of the study. These data confirm the essential clinical great things about ADVATE when utilized as a prophylactic therapy to lessen bleeding episodes. The analysis results demonstrated a statistically significant decrease in the median annual bleeding price, with patients experiencing 44 bleeds during on-demand treatment in comparison to one bleed while on either of the prophylactic regimens evaluated, a 98 % decrease in annual bleed price .Targeting malignancy cells with AXL1717 rather than conventional cytotoxic chemotherapy could become a highly effective and well-tolerated treatment alternate for cancer patients later on’.. COTI’s novel small molecule effective against pancreatic cancer in animal model Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This fresh series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as an individual agent and in combination with current first series therapies, as well as low toxicity in several different animal models of human cancers.